Kenvue Inc. (NYSE:KVUE) Shares Sold by Gotham Asset Management LLC

Gotham Asset Management LLC cut its holdings in Kenvue Inc. (NYSE:KVUE) by 11.1% during the fourth quarter, HoldingsChannel reports. The fund owned 219,638 shares of the company’s stock after selling 27,534 shares during the period. Gotham Asset Management LLC’s holdings in Kenvue were worth $4,689,000 at the end of the most recent quarter.

A number of other large investors have also recently added to or reduced their stakes in KVUE. Grove Bank & Trust raised its position in Kenvue by 438.4% in the fourth quarter. Grove Bank & Trust now owns 1,163 shares of the company’s stock valued at $25,000 after purchasing an additional 947 shares during the period. Geneos Wealth Management Inc. purchased a new position in shares of Kenvue during the 4th quarter worth $29,000. SRS Capital Advisors Inc. increased its position in shares of Kenvue by 67.4% during the 4th quarter. SRS Capital Advisors Inc. now owns 1,418 shares of the company’s stock worth $30,000 after purchasing an additional 571 shares during the last quarter. Asset Planning Inc purchased a new stake in Kenvue in the 4th quarter valued at about $42,000. Finally, Clarity Asset Management Inc. purchased a new stake in Kenvue in the 4th quarter valued at about $45,000. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Kenvue Stock Performance

Shares of KVUE stock opened at $23.26 on Thursday. The firm has a 50 day moving average of $23.15 and a two-hundred day moving average of $22.58. The stock has a market capitalization of $44.63 billion, a PE ratio of 43.89, a P/E/G ratio of 2.62 and a beta of 1.02. The company has a quick ratio of 0.69, a current ratio of 1.00 and a debt-to-equity ratio of 0.66. Kenvue Inc. has a 52 week low of $17.67 and a 52 week high of $25.17.

Kenvue (NYSE:KVUE) last released its earnings results on Thursday, May 8th. The company reported $0.24 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.23 by $0.01. Kenvue had a return on equity of 20.97% and a net margin of 6.66%. The firm had revenue of $3.74 billion during the quarter, compared to analyst estimates of $3.69 billion. During the same period last year, the business posted $0.28 earnings per share. Kenvue’s revenue was down 3.9% compared to the same quarter last year. On average, research analysts predict that Kenvue Inc. will post 1.14 EPS for the current fiscal year.

Kenvue Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, May 28th. Stockholders of record on Wednesday, May 14th will be paid a $0.205 dividend. This represents a $0.82 annualized dividend and a dividend yield of 3.53%. The ex-dividend date is Wednesday, May 14th. Kenvue’s payout ratio is presently 149.09%.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on KVUE shares. Citigroup increased their target price on shares of Kenvue from $22.00 to $24.50 and gave the stock a “neutral” rating in a research note on Friday, May 9th. Royal Bank of Canada reaffirmed a “sector perform” rating and set a $24.00 price objective on shares of Kenvue in a research report on Monday, February 3rd. Piper Sandler boosted their target price on Kenvue from $24.00 to $27.00 and gave the company an “overweight” rating in a research report on Monday, February 24th. Barclays upped their price target on Kenvue from $22.00 to $23.00 and gave the stock an “equal weight” rating in a research note on Monday. Finally, Redburn Atlantic initiated coverage on Kenvue in a research note on Thursday, April 10th. They issued a “neutral” rating and a $23.50 price objective for the company. Seven research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat.com, Kenvue currently has a consensus rating of “Hold” and an average price target of $25.33.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.